C
Chaan S. Ng
Researcher at University of Texas MD Anderson Cancer Center
Publications - 153
Citations - 8045
Chaan S. Ng is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Cancer & Perfusion scanning. The author has an hindex of 44, co-authored 152 publications receiving 7204 citations.
Papers
More filters
Journal ArticleDOI
Phase II Trial of Curcumin in Patients with Advanced Pancreatic Cancer
Navneet Dhillon,Bharat B. Aggarwal,Robert A. Newman,Robert A. Wolff,Ajaikumar B. Kunnumakkara,James L. Abbruzzese,Chaan S. Ng,Vladimir Badmaev,Razelle Kurzrock +8 more
TL;DR: Oral curcumin is well tolerated and, despite its limited absorption, has biological activity in some patients with pancreatic cancer.
Journal ArticleDOI
NRAS mutation status is an independent prognostic factor in metastatic melanoma.
John A. Jakob,Roland L. Bassett,Chaan S. Ng,Jonathan L. Curry,Richard W. Joseph,Gladys Alvarado,Michelle Rohlfs,Jessie Richard,Jeffrey E. Gershenwald,Kevin B. Kim,Alexander J. Lazar,Patrick Hwu,Michael A. Davies +12 more
TL;DR: The prognostic significance and clinicopathologic correlations of v‐raf murine sarcoma viral oncogene homolog B1 (BRAF) and neuroblastoma RAS viral (v‐ras) oncogen homolog (NRAS) mutations in patients with metastatic melanoma are tested.
Journal ArticleDOI
Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer
Razelle Kurzrock,Steven I. Sherman,Douglas W. Ball,Arlene A. Forastiere,Roger B. Cohen,Ranee Mehra,David G. Pfister,Ezra E.W. Cohen,Linda Janisch,Forlisa Nauling,David S. Hong,Chaan S. Ng,Lei Ye,Robert F. Gagel,John W. Frye,Thomas Müller,Mark J. Ratain,Ravi Salgia +17 more
TL;DR: Cabozantinib has an acceptable safety profile and is active in MTC, and may provide clinical benefit by simultaneously targeting multiple pathways of importance in M TC, including MET, VEGFR2, and RET.
Journal ArticleDOI
Comparison of CT Methods for Determining the Fat Content of the Liver
Yoshihisa Kodama,Chaan S. Ng,Tsung T. Wu,Gregory D. Ayers,Steven A. Curley,Eddie K. Abdalla,Jean Nicolas Vauthey,Chusilp Charnsangavej +7 more
TL;DR: Measurement of attenuation of liver only on unenhanced CT scans is best for prediction of pathologic fat content, as well as a number of methods of measuring attenuation on CT scans, for predicting hepatic fat content.
Journal ArticleDOI
Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non–Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial
Nizar M. Tannir,Eric Jonasch,Laurence Albiges,Emre Altinmakas,Chaan S. Ng,Surena F. Matin,Xuemei Wang,Wei Qiao,Zita Dubauskas Lim,Pheroze Tamboli,Priya Rao,Kanishka Sircar,Jose A. Karam,David F. McDermott,Christopher G. Wood,Toni K. Choueiri +15 more
TL;DR: This randomized phase 2 trial provides the first head-to-head comparison of everolimus and sunitinib in patients with metastatic non-clear cell renal cell carcinoma (non-ccRCC).